Literature DB >> 16039614

Activation of ERK during DNA damage-induced apoptosis involves protein kinase Cdelta.

Alakananda Basu1, Haidi Tu.   

Abstract

We have previously shown that protein kinase C (PKC) acts upstream of caspases to regulate cisplatin-induced apoptosis. Since extracellular signal-regulated kinases (ERKs) have also been implicated in DNA damage-induced apoptosis, we have examined if ERK signaling pathway acts downstream of PKC in the regulation of cisplatin-induced apoptosis. PKC activator PDBu induced ERK1/2 phosphorylation which was inhibited by general PKC inhibitor bisindolylmaleimide and Gö 6983 as well as the MEK inhibitor U0126 but not by the PKCdelta inhibitor rottlerin. Cisplatin caused a concentration-dependent activation of ERK1/2 in HeLa cells. The level of ERK2 was decreased in HeLa cells that acquired resistance to cisplatin (HeLa/CP). The MEK inhibitor U0126 inhibited cisplatin-induced ERK activation and attenuated cisplatin-induced cell death. Inhibition of PKCdelta by rottlerin or depletion of PKCdelta by siRNA inhibited cisplatin-induced ERK activation. These results suggest that cisplatin-induced DNA damage results in activation of ERK1/2 via PKCdelta.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16039614     DOI: 10.1016/j.bbrc.2005.06.199

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

1.  Downregulation of mitogen-activated protein kinase 1 of Leishmania donovani field isolates is associated with antimony resistance.

Authors:  Mansi Garg; Shyam Sundar; Robert Duncan; Hira L Nakhasi; Neena Goyal
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  Sublethal concentrations of the platinum(II) complex [Pt(O,O'-acac)(gamma-acac)(DMS)] alter the motility and induce anoikis in MCF-7 cells.

Authors:  Antonella Muscella; Nadia Calabriso; Carla Vetrugno; Loredana Urso; Francesco Paolo Fanizzi; Sandra Angelica De Pascali; Santo Marsigliante
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 3.  Multifunctional roles of PKCδ: Opportunities for targeted therapy in human disease.

Authors:  Mary E Reyland; David N M Jones
Journal:  Pharmacol Ther       Date:  2016-05-11       Impact factor: 12.310

4.  Protein kinase Cδ oxidation contributes to ERK inactivation in lupus T cells.

Authors:  Gabriela J Gorelik; Sushma Yarlagadda; Dipak R Patel; Bruce C Richardson
Journal:  Arthritis Rheum       Date:  2012-09

5.  A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines.

Authors:  Piotr Jasinski; Brandon Welsh; Jorge Galvez; David Land; Pawel Zwolak; Lori Ghandi; Kaoru Terai; Arkadiusz Z Dudek
Journal:  Invest New Drugs       Date:  2007-10-24       Impact factor: 3.850

6.  Cellular responses to Cisplatin-induced DNA damage.

Authors:  Alakananda Basu; Soumya Krishnamurthy
Journal:  J Nucleic Acids       Date:  2010-08-08

Review 7.  Cisplatin in cancer therapy: molecular mechanisms of action.

Authors:  Shaloam Dasari; Paul Bernard Tchounwou
Journal:  Eur J Pharmacol       Date:  2014-07-21       Impact factor: 4.432

Review 8.  Signalling mechanisms involved in renal pathological changes during cisplatin-induced nephropathy.

Authors:  Siddesh Jaiman; Arun Kumar Sharma; Kulwant Singh; Deepa Khanna
Journal:  Eur J Clin Pharmacol       Date:  2013-08-09       Impact factor: 2.953

9.  Activating deltaPKC antagonizes the protective effect of ERK1/2 inhibition against stroke in rats.

Authors:  Dora Castañeda; Heng Zhao; Daria Mochly-Rosen; Gary K Steinberg
Journal:  Brain Res       Date:  2008-11-27       Impact factor: 3.252

Review 10.  Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway.

Authors:  Iman W Achkar; Nabeel Abdulrahman; Hend Al-Sulaiti; Jensa Mariam Joseph; Shahab Uddin; Fatima Mraiche
Journal:  J Transl Med       Date:  2018-04-11       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.